Claims for Patent: 4,559,300

Summary for Patent: 4,559,300

Title:	Method for using an homologous bacillus promoter and associated natural or modified ribosome binding site-containing DNA sequence in streptomyces
Abstract:	A method for expressing a functional polypeptide in Streptomyces comprises transforming a Streptomyces host cell with a recombinant DNA expression vector and then culturing the transformed cell under conditions suitable for cell growth. The recombinant DNA expression vector comprises the veg or any other homologous Bacillus promoter, a naturally occurring or modified ribosome binding site-containing DNA sequence and a gene that codes for a functional polypeptide such as human pre-proinsulin. The method is specifically exemplified by use of expression plasmids pOW529, pOW539 and transformants, Streptomyces ambofaciens/pOW529 and Streptomyces ambofaciens/pOW539. The method is broadly applicable and is particularly useful in economically important Streptomyces taxa.
Inventor(s):	Kovacevic; Steven (Indianapolis, IN), Fayerman; Jeffrey T. (Indianapolis, IN), Miller; James R. (Indianapolis, IN), Richardson; Mark A. (Indianapolis, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	06/458,803
Patent Claims:	1. A method for expressing a functional polypeptide in Streptomyces comprising transforming a Streptomyces host cell with a recombinant DNA expression vector, said vector comprising (1) a homologous Bacillus promoter, (2) Bacillus ribosome binding site-containing DNA sequence, and (3) a gene encoding a functional polypeptide and culturing said transformed Streptomyces cell under growing conditions, subject to the limitations that said vector replicates and is selectable in said transformed Streptomyces cell and that said promoter and said DNA sequence direct transcription and expression of said gene in said transformed Streptomyces host cell. 2. A method for expressing a functional polypeptide in Streptomyces comprising transforming a Streptomyces host cell with a recombinant DNA expression vector said vector comprising (1) the ribosome binding site-containing DNA sequence ##STR4## wherein A is deoxyadenyl, G is deoxyguanyl, C is deoxycytosyl, T is thymidyl, R is G or C, R.sup.1 is G or C, and R.sup.2 is G or T, (2) the veg promoter of Bacillus subtilis, and (3) a gene encoding a functional polypeptide, and culturing said transformed Streptomyces cell under growing conditions, subject to the limitations that said vector replicates and is selectable in said transformed Streptomyces cell and that said promoter and said DNA sequence direct transcription and expression of said gene in said transformed Streptomyces host cell, and subject to the further limitation that (1) R and R.sup.1 are not simultaneously the same deoxyribonucleotide and (2) when R.sup.2 is T, then R is G and R.sup.1 is C. 3. The method of claim 1 wherein the expression vector is a plasmid. 4. The method of claim 2 wherein the expression vector is a plasmid. 5. The method of claim 3 wherein the gene that encodes a functional polypeptide is selected from the group consisting of genes that encode human preproinsulin, human proinsulin, human insulin A-chain, human insulin B-chain, non-human insulin, human growth hormone non-human growth hormone, bovine growth hormone, porcine growth hormone, human interferon, non-human interferon, viral antigen, urokinse, polypeptide hormone and polypeptide enzyme. 6. The method of claim 5 in which the gene encodes human pre-proinsulin. 7. The method of claim 5 in which the gene encodes human proinsulin. 8. The method of claim 5 in which the gene encodes human insulin A-chain. 9. The method of claim 5 in which the gene encodes human insulin B-chain. 10. The method of claim 5 in which the gene encodes non-human insulin. 11. The method of claim 5 in which the gene encodes human growth hormone. 12. The method of claim 5 in which the gene encodes non-human growth hormone. 13. The method of claim 5 in which the gene encodes bovine growth hormone. 14. The method of claim 5 in which the gene encodes porcine growth hormone. 15. The method of claim 5 in which the gene encodes human interferon. 16. The method of claim 5 in which the gene encodes viral antigen. 17. The method of claim 5 in which the gene encodes a polypeptide hormone. 18. the method of claim 5 in which the gene encodes an enzyme. 19. The method of claim 2 wherein the recombinant DNA expression vector is selected from the group consisting of plasmids pOW527, pOW528, pOW529, pOW530, pOW533, pOW534, pOW537, pOW538, pOW539 and pOW540. 20. The method of claim 19 wherein the plasmid is pOW527. 21. The method of claim 19 wherein the plasmid is pOW528. 22. The method of claim 19 wherein the plasmid is pOW529. 23. The method of claim 19 wherein the plasmid is pOW530. 24. The method of claim 19 wherein the plasmid is pOW533. 25. The method of claim 19 wherein the plasmid is pOW534. 26. The method of claim 19 wherein the plasmid is pOW537. 27. The method of claim 19 wherein the plasmid is pOW538. 28. The method of claim 19 wherein the plasmid is pOW539. 29. The method of claim 19 wherein the plasmid is pOW540. 30. The method of claim 2 wherein the ribosome binding site-containing DNA sequence is ##STR5## wherein A is deoxyadenyl, G is deoxyguanyl, C is deoxycytosyl, T is thymidyl, R is G or C, and R.sup.1 is G or C subject to the limitation that R and R.sup.1 are not simultaneously the same deoxyribonucleotide. 31. The method of claim 2 in which the transformed Streptomyces host cell is Streptomyces ambofaciens. 32. The method of claim 5 in which the transformed Streptomyces host cell is Streptomyces ambofaciens. 33. The method of claim 7 in which the transformed Streptomyces host cell is Streptomyces ambofaciens. 34. The method of claim 8 in which the transformed Streptomyces host cell is Streptomyces ambofaciens. 35. The method of claim 11 in which the transformed Streptomyces host cell is Streptomyces ambofaciens. 36. The method of claim 13 in which the transformed Streptomyces host cell is Streptomyces ambofaciens. 37. The method of claim 14 in which the transformed Streptomyces host cell is Streptomyces ambofaciens. 38. The method of claim 19 in which the transformed Streptomyces host cell is Streptomyces ambofaciens. 39. The method of claim 20 in which the transformed Streptomyces host cell is Streptomyces ambofaciens. 40. The method of claim 22 in which the transformed Streptomyces host cell is Streptomyces ambofaciens. 41. The method of claim 24 in which the transformed Streptomyces host cell is Streptomyces ambofaciens. 42. The method of claim 26 in which the transformed Streptomyces host cell is Streptomyces ambofaciens. 43. The method of claim 28 in which the transformed Streptomyces host cell is Streptomyces ambofaciens. 44. A transformed Streptomyces host cell of claim 1. 45. A transformed Streptomyces host cell of claim 2. 46. The transformed Streptomyces host cell of claim 45 wherein the gene that encodes a functional polypeptide is selected from the group consisting of genes that encode human pre-proinsulin, human proinsulin, human insulin A-chain, human insulin B-chain, non-human insulin, human growth hormone, non-human growth hormone, bovine growth hormone, procine growth hormone, human interferon, non-human interferon, viral antigen, urokinase, polypeptide hormone and polypeptide enzyme. 47. The transformed Streptomyces host cell of claim 46 in which the gene encodes human proinsulin. 48. The transformed Streptomyces host cell of claim 46 in which the gene encodes human insulin A-chain. 49. The transformed Streptomyces host cell of claim 46 in which the gene encodes human growth hormone. 50. The transformed Streptomyces host cell of claim 46 in which the gene encodes bovine growth hormone. 51. The transformed Streptomyces host cell of claim 46 in which the gene encodes porcine growth hormone. 52. The transformed Streptomyces host cell of claim 44 wherein the recombinant DNA expression vector is selected from the group consisting of plasmids pOW527, pOW528, pOW529, pOW530, pOW533, pOW534, pOW537, pOW538, pOW539 and pOW540. 53. The transformed host cell of claim 52 which is Streptomyces ambofaciens/pOW527. 54. The transformed host cell of claim 52 which is Streptomyces ambofaciens/pOW529. 55. The transformed host cell of claim 52 which is Streptomyces ambofaciens/pOW533. 56. The transformed host cell of claim 52 which is Streptomyces ambofaciens/pOW537. 57. The transformed host cell of claim 52 which is Streptomyces ambofaciens/pOW539. 58. The transformed host cell of claim 52 which is Streptomyces ambofaciens/pOW540.

Details for Patent 4,559,300

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	October 28, 1982	4,559,300	2003-01-18
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	December 29, 2015	4,559,300	2003-01-18
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	August 06, 1998	4,559,300	2003-01-18
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	March 31, 1994	4,559,300	2003-01-18
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	May 25, 2018	4,559,300	2003-01-18